A Phase 3 interventional study of Placebo and Cariprazine in Schizophrenia, sponsored by Forest Laboratories. Completed at 73 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-07-06.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one has the largest enrollment, is one of 2 that started in 2011, is one of 8 in phase 3, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 2 started in 2011.
This study's enrollment of 765 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
27 studies in Schizophrenia by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 27 studies in Schizophrenia by AbbVie, this one has the largest enrollment, is one of 2 that started in 2011, is one of 8 in phase 3, and was the 12th registered.
AbbVie’s Schizophrenia studies by the year they started, since 2004.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
There were 3 periods (phases) in the study. The Open-label Phase lasted 20 weeks. In the first 6 weeks, participants received 3, 6, or 9 mg cariprazine orally once a day; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this Open-label Phase. At the end of Week 8, participants had to meet the following criteria to continue in the study.
At the end of the Open-label Phase, participants were randomized into 2 treatment groups, cariprazine or placebo, if they met the following criteria:
All participants entered the 4 week Safety Follow-up Phase. They received a treatment other than the investigational product at the discretion of the Investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
Drug: Cariprazine
Participants received placebo orally once a day for 26 to 72 weeks.
Drug: Placebo
Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
Drug: Cariprazine
Placebo was supplied in capsules.
Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
Also known as: RGH-188
Time From Baseline to the First Symptom Relapse During the Double-blind Phase
Relapse was defined as meeting ≥1 of the following criteria:1-Hospitalization due to worsening of condition;2-increase in Positive and Negative Syndrome Scale(PANSS) total score by ≥30% for participants,scored ≥50 or a ≥10-point increase for participants,scored \<50 at randomization;3-increase in Clinical Global Impressions-Severity(CGI-S) score by ≥2 points at Week 20;4-deliberate self-injury or aggressive behaviour;5-suicidal/homicidal ideation judged clinically significant by Investigator;6-score of \>4 on 1 or more of following PANSS items:P1,P2,P3,P6,P7,G8 or G14. Second assessment not performed based on Investigator discretion. PANSS is 30-item rating scale. Each item scored on 7-point scale. Total score ranges from 30 to 210. Lower score indicates fewer schizophrenic symptoms. CGI-S is 7-point scale,measures severity of participant's illness in comparison with others with same diagnosis. Lower score indicates less severe illness. 25th percentile for time to relapse was reported.
Time frame: Up to 34 Weeks and Bi-Weekly thereafter until Week 92
| Milestone | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 765 | 0 | 0 |
| Completed | 418 | 0 | 0 |
| Not completed | 347 | 0 | 0 |
| Withdrew: Adverse event | 86 | 0 | 0 |
| Withdrew: Insufficient therapeutic response | 66 | 0 | 0 |
| Withdrew: Protocol violation | 27 | 0 | 0 |
| Withdrew: Withdrawal of consent | 117 | 0 | 0 |
| Withdrew: Lost to follow-up | 32 | 0 | 0 |
| Withdrew: Other miscellaneous reasons | 19 | 0 | 0 |
| Milestone | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 418 | 0 | 0 |
| Completed | 364 | 0 | 0 |
| Not completed | 54 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 |
| Withdrew: Insufficient therapeutic response | 19 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Withdrawal of consent | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 0 | 0 |
| Withdrew: Other miscellaneous reasons | 23 | 0 | 0 |
| Milestone | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 364 | 0 | 0 |
| Completed | 264 | 0 | 0 |
| Not completed | 100 | 0 | 0 |
| Withdrew: Adverse event | 9 | 0 | 0 |
| Withdrew: Insufficient therapeutic response | 9 | 0 | 0 |
| Withdrew: Protocol violation | 14 | 0 | 0 |
| Withdrew: Withdrawal of consent | 40 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 0 | 0 |
| Withdrew: Other miscellaneous reasons | 19 | 0 | 0 |
| Milestone | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 264 | 0 | 0 |
| Completed | 200 | 0 | 0 |
| Not completed | 64 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Withdrawal of consent | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Did not met criteria to enter next phase | 4 | 0 | 0 |
| Withdrew: Other miscellaneous reasons | 55 | 0 | 0 |
| Milestone | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 0 | 99 | 101 |
| Completed | 0 | 16 | 18 |
| Not completed | 0 | 83 | 83 |
| Withdrew: Adverse event | 0 | 5 | 6 |
| Withdrew: Protocol violation | 0 | 4 | 5 |
| Withdrew: Withdrawal of consent | 0 | 10 | 15 |
| Withdrew: Lost to follow-up | 0 | 6 | 5 |
| Withdrew: Other miscellaneous reasons | 0 | 11 | 27 |
| Withdrew: Relapse | 0 | 47 | 25 |
Relapse was defined as meeting ≥1 of the following criteria:1-Hospitalization due to worsening of condition;2-increase in Positive and Negative Syndrome Scale(PANSS) total score by ≥30% for participants,scored ≥50 or a ≥10-point increase for participants,scored \<50 at randomization;3-increase in Clinical Global Impressions-Severity(CGI-S) score by ≥2 points at Week 20;4-deliberate self-injury or aggressive behaviour;5-suicidal/homicidal ideation judged clinically significant by Investigator;6-score of \>4 on 1 or more of following PANSS items:P1,P2,P3,P6,P7,G8 or G14. Second assessment not performed based on Investigator discretion. PANSS is 30-item rating scale. Each item scored on 7-point scale. Total score ranges from 30 to 210. Lower score indicates fewer schizophrenic symptoms. CGI-S is 7-point scale,measures severity of participant's illness in comparison with others with same diagnosis. Lower score indicates less severe illness. 25th percentile for time to relapse was reported.
| Days | Placebo | Cariprazine |
|---|---|---|
| Time From Baseline to the First Symptom Relapse During the Double-blind Phase | 92 (44 to 151) | 224 (99 to NA) |
Collected over First dose until 30 days after last dose of investigational product [Open-Label (Up to 184 days) and Double-Blind (Up to 536 days)]. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cariprazine - Open-label Phase | 0/765 (0%) | 50/765 (6.5%) | 425/765 (55.6%) |
| Placebo - Double-blind Treatment Phase | 0/99 (0%) | 14/99 (14.1%) | 28/99 (28.3%) |
| Cariprazine - Double-blind Treatment Phase | 0/101 (0%) | 14/101 (13.9%) | 35/101 (34.7%) |
| Open-label - Safety Follow-up Phase | 0/765 (0%) | 6/765 (0.8%) | 0/765 (0%) |
| Placebo - Safety Follow-up Phase | 0/99 (0%) | 2/99 (2%) | 0/99 (0%) |
| Cariprazine - Safety Follow-up Phase | 0/101 (0%) | 0/101 (0%) | 0/101 (0%) |
| Event | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase | Open-label - Safety Follow-up Phase | Placebo - Safety Follow-up Phase | Cariprazine - Safety Follow-up Phase |
|---|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 19/765 | 7/99 | 5/101 | 3/765 | 0/99 | 0/101 |
| Psychotic disorderPsychiatric disorders | 10/765 | 2/99 | 2/101 | 3/765 | 1/99 | 0/101 |
| Schizophrenia, paranoid typePsychiatric disorders | 3/765 | 0/99 | 2/101 | 0/765 | 0/99 | 0/101 |
| Atrial fibrillationCardiac disorders | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Cholecystitis acuteHepatobiliary disorders | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Generalised tonic-clonic seizureNervous system disorders | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Ischaemic strokeNervous system disorders | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Middle ear effusionEar and labyrinth disorders | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Otitis media acuteInfections and infestations | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Sinus tachycardiaCardiac disorders | 0/765 | 1/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| Event | Cariprazine - Open-label Phase | Placebo - Double-blind Treatment Phase | Cariprazine - Double-blind Treatment Phase | Open-label - Safety Follow-up Phase | Placebo - Safety Follow-up Phase | Cariprazine - Safety Follow-up Phase |
|---|---|---|---|---|---|---|
| AkathisiaNervous system disorders | 148/765 | 0/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| InsomniaPsychiatric disorders | 110/765 | 8/99 | 8/101 | 0/765 | 0/99 | 0/101 |
| HeadacheNervous system disorders | 92/765 | 7/99 | 8/101 | 0/765 | 0/99 | 0/101 |
| RestlessnessPsychiatric disorders | 70/765 | 0/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| NasopharyngitisInfections and infestations | 0/765 | 5/99 | 8/101 | 0/765 | 0/99 | 0/101 |
| TremorNervous system disorders | 0/765 | 0/99 | 8/101 | 0/765 | 0/99 | 0/101 |
| Extrapyramidal disorderNervous system disorders | 55/765 | 3/99 | 6/101 | 0/765 | 0/99 | 0/101 |
| Weight increasedInvestigations | 49/765 | 0/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| NauseaGastrointestinal disorders | 48/765 | 0/99 | 0/101 | 0/765 | 0/99 | 0/101 |
| SchizophreniaPsychiatric disorders | 0/765 | 6/99 | 4/101 | 0/765 | 0/99 | 0/101 |
Run-in Phase safety population: All participants who received at least 1 dose of open-label cariprazine during the Run-in Phase of the study.
| Age, Continuous(years) | Cariprazine - Open-label Phase |
|---|---|
| Mean | 38.4 ± 10.4 |
| Sex: Female, Male(Participants) | Cariprazine - Open-label Phase |
|---|---|
| Female | 221 |
| Male | 544 |
| Ethnicity (NIH/OMB)(Participants) | Cariprazine - Open-label Phase |
|---|---|
| Hispanic or Latino | 37 |
| Not Hispanic or Latino | 728 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Cariprazine - Open-label Phase |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 149 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 313 |
| White | 299 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Weight(kg) | Cariprazine - Open-label Phase |
|---|---|
| Mean | 78.07 ± 20.10 |
| Height(cm) | Cariprazine - Open-label Phase |
|---|---|
| Mean | 170.98 ± 9.95 |
| Body Mass Index (BMI)(kg/m^2) | Cariprazine - Open-label Phase |
|---|---|
| Mean | 26.50 ± 5.63 |
| Waist circumference(cm) | Cariprazine - Open-label Phase |
|---|---|
| Mean | 90.39 ± 15.34 |
Ran from Sep 2011 to primary completion in Sep 2014, 35 months.
Results were first posted in Jul 2018, 3 years 10 months after primary completion. A results delay was requested in Sep 2015.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 35 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine